At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SHPH Shuttle Pharmaceuticals Inc
Trading 11-05 14:31:02 EST
1.41
-0.19
-11.87%
High1.70Low1.34Vol185.04K
Open1.61D1 Closing1.60Amplitude22.50%
Mkt Cap4.15MTradable Cap2.93MTotal Shares2.95M
T/O275.90KT/O Rate8.91%Tradable Shares2.08M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Shuttle Pharmaceuticals Prices $4.5 Million Public Offering
MT Newswires Live  ·  10-30
Shuttle Pharmaceuticals Prices $4.5 Million Public Offering
Shuttle Pharmaceuticals dips 6%, prices $4.5M share offering
seekingalpha  ·  10-30
Shuttle Pharmaceuticals dips 6%, prices $4.5M share offering
BRIEF-Shuttle Pharmaceuticals Holdings Announces Pricing Of $4.5 Mln Public Offering
Reuters  ·  10-30
BRIEF-Shuttle Pharmaceuticals Holdings Announces Pricing Of $4.5 Mln Public Offering
Shuttle Pharmaceuticals prices $4.5M at-the-market offering at $1.525 per share
TIPRANKS  ·  10-30
Shuttle Pharmaceuticals prices $4.5M at-the-market offering at $1.525 per share
Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced at-the-Market Under Nasdaq Rules
THOMSON REUTERS  ·  10-30
Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced at-the-Market Under Nasdaq Rules
Shuttle Pharmaceuticals Holdings Inc - Prices Public Offering of up to 2.9 Mln Shares of Common Stock and Warrants at$1.525 per Share
THOMSON REUTERS  ·  10-30
Shuttle Pharmaceuticals Holdings Inc - Prices Public Offering of up to 2.9 Mln Shares of Common Stock and Warrants at$1.525 per Share
Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
GlobeNewswire  ·  10-30
Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
Shuttle Pharma Pays off Senior Secured Convertible Note
THOMSON REUTERS  ·  10-30
Shuttle Pharma Pays off Senior Secured Convertible Note
Shuttle Pharma Pays Off Senior Secured Convertible Note
GlobeNewswire  ·  10-30
Shuttle Pharma Pays Off Senior Secured Convertible Note
US Stocks Mixed; McDonald's Posts Upbeat Earnings
Benzinga  ·  10-29
US Stocks Mixed; McDonald's Posts Upbeat Earnings
Shuttle Pharmaceuticals doses first patients in Phase 2 trial of Ropidoxuridine
TIPRANKS  ·  10-29
Shuttle Pharmaceuticals doses first patients in Phase 2 trial of Ropidoxuridine
Shuttle Pharma Doses First Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients With Glioblastoma
THOMSON REUTERS  ·  10-29
Shuttle Pharma Doses First Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients With Glioblastoma
Shuttle Pharmaceuticals Soars Premarket Following Completion of Phase 2 Glioblastoma Trial Site Enrollment
MT Newswires Live  ·  10-29
Shuttle Pharmaceuticals Soars Premarket Following Completion of Phase 2 Glioblastoma Trial Site Enrollment
Shuttle Pharmaceuticals Shares Rise 63% on Drug-Study Site Update
Dow Jones  ·  10-29
Shuttle Pharmaceuticals Shares Rise 63% on Drug-Study Site Update
BRIEF-Shuttle Pharma Completes Clinical Trial Site Enrollment For Phase 2 Of Ropidoxuridine For Treatment Of Patients With Glioblastoma
Reuters  ·  10-29
BRIEF-Shuttle Pharma Completes Clinical Trial Site Enrollment For Phase 2 Of Ropidoxuridine For Treatment Of Patients With Glioblastoma
Shuttle’s clinical trial site enrollments complete for Phase 2 of IPdR for GBM
TIPRANKS  ·  10-29
Shuttle’s clinical trial site enrollments complete for Phase 2 of IPdR for GBM
Shuttle Pharma Completes Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients With Glioblastoma
THOMSON REUTERS  ·  10-29
Shuttle Pharma Completes Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients With Glioblastoma
Shuttle Pharmaceuticals Holdings Inc - Trial Expected to Be Completed in 18-24 Months
THOMSON REUTERS  ·  10-29
Shuttle Pharmaceuticals Holdings Inc - Trial Expected to Be Completed in 18-24 Months
Shuttle Pharma Completes Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma
GlobeNewswire  ·  10-29
Shuttle Pharma Completes Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma
Shuttle Pharmaceuticals to Present at the 2024 ThinkEquity Conference on Wednesday, October 30, 2024
GlobeNewswire  ·  10-28
Shuttle Pharmaceuticals to Present at the 2024 ThinkEquity Conference on Wednesday, October 30, 2024
No data available

Introduction

Company Name.
Shuttle Pharmaceuticals Inc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas, SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers. The company was founded in 2012 and is based in Rockville, Maryland.
Issue price:
--